Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
企業コードGCTK
会社名GlucoTrack Inc
上場日Apr 09, 2013
最高経営責任者「CEO」Mr. Paul V. Goode, Ph.D.
従業員数11
証券種類Ordinary Share
決算期末Apr 09
本社所在地301 Rt 17 North
都市RUTHERFORD
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号07070
電話番号197286757878
ウェブサイト
企業コードGCTK
上場日Apr 09, 2013
最高経営責任者「CEO」Mr. Paul V. Goode, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし